Published Date: 4/09/2024
In a significant move to revolutionize the diagnosis and treatment of heart disease, Viz.ai, a pioneer in AI-powered disease detection, has partnered with Cleerly, a company dedicated to creating a new standard of care for heart disease. This collaboration aims to integrate Cleerly's advanced cardiovascular diagnostic tools into the Viz.ai One platform, enhancing the care coordination process for patients with heart disease.
The Viz.ai One platform, used by clinicians in over 1,600 hospitals, will now incorporate Cleerly's AI-enabled digital care platform, which analyzes non-invasive coronary computed tomography angiography (CCTA) images to detect ischemia and stenosis, and identify, quantify, and categorize plaque. This integration will enable clinicians to provide personalized treatment plans for patients across the care continuum.
"Q: What is the partnership between Viz.ai and Cleerly about?
A: The partnership aims to integrate Cleerly's advanced cardiovascular diagnostic tools into the Viz.ai One platform, enhancing the care coordination process for patients with heart disease.
Q: What is Cleerly's technology used for?
A: Cleerly's AI-enabled digital care platform analyzes non-invasive coronary computed tomography angiography (CCTA) images to detect ischemia and stenosis, and identify, quantify, and categorize plaque.
Q: How will this partnership impact patient care?
A: The partnership will enable clinicians to provide personalized treatment plans for patients across the care continuum, ultimately enhancing access to life-saving treatments and improving patient outcomes.
Q: What is Viz.ai's mission?
A: Viz.ai is committed to collaborating with industry-leading companies to improve clinical impact and provide quick access to important patient data.
Q: What is Cleerly's mission?
A: Cleerly is on a mission to eliminate heart attacks by creating a new standard of care for heart disease through its FDA-cleared solutions driven by artificial intelligence.